, Volume 99, Issue 1, pp 48–53 | Cite as

An evaluation of the elevated plus-maze test using the novel anxiolytic buspirone

  • P. C. Moser
Original Investigations


Previous work suggests that the elevated plusmaze test of anxiety is insensitive to the anxiolytic effects of the novel anxiolytic buspirone, which shows an anxiogenic-like profile in this test. This paper examines some of the possible reasons for this and the role that buspirone's agonist activity at 5-HT1A receptors plays in this effect. A variety of 5-HT1A receptor agonists (p-aminophenylethylm-trifluromethylphenyl piperazine, (+)- and (-)-MDL 72832) showed similar activity to buspirone, as did the related compound ipsapirone. (-)-MDL 72832 was more potent than (+)-MDL 72832, in keeping with its stereoselective action at 5-HT1A receptors. The α2-adrenoceptor antagonist properties of 1-pyrimidinyl piperazine, a metabolite of buspirone, did not appear to be relevant to this action of buspirone as neither it nor idazoxan showed an anxiogenic-like profile. Neither chronic treatment with buspirone (1 mg/kg SC twice a day for 16 days) nor depletion of 5-HT withp-chlorophenylalanine changed the anxiogenic-like activity of buspirone in the elevated plus-maze test. These results suggest that an agonist action at postsynaptic 5-HT1A receptors mediates the anxiogenic-like effects of buspirone in the elevated plus-maze test and that this test may either be insensitive to certain classes of anxiolytics or is measuring something unrelated to human anxiety states.

Key words

Buspirone Elevated plus-maze test 5-Hydroxytryptamine1A receptors Anxiety 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Basse-Tomusk A, Rebec GV (1986) Ipsapirone depresses neuronal activity in the dorsal raphé nucleus and hippocampal formation. Eur J Pharmacol 130:141–143Google Scholar
  2. Broadhurst PL (1957) Determinants of emotionality in the rat. 1. Situational factors. Br J Pharmacol 48:1–12Google Scholar
  3. Chopin P, Briley M (1987) Animal models of anxiety: the effect of compounds that modify 5-HT neurotransmission. TIPS 8:383–388Google Scholar
  4. Clague R, Spedding M (1987) Selective interactions of buspirone, WB 4101 and prazosin with 8-OH-DPAT and RU 24969 in the rat. Br J Pharmacol 90:252PGoogle Scholar
  5. Critchley MAE, Handley SL (1987a) Effects in the X-maze anxiety model of agents acting at 5-HT1 and 5-HT2 receptors. Psychopharmacology 93:502–506Google Scholar
  6. Critchley MAE, Handley SL (1987b) 5-HT1A ligand effects in the X-maze anxiety test. Br J Pharmacol 92:660PGoogle Scholar
  7. De Vivo M, Maayani S (1986) Characterisation of the 5-hydroxytryptamine1A receptor-mediated inhibition of forskolin-stimulated adenylate cyclase activity in guinea pig and rat hippocampal membranes. J Pharmacol Exp Ther 238:248–253Google Scholar
  8. Dompert WU, Glaser T Traber J (1985)3H-TVX Q 7821: identification of 5-HT1 binding sites as target for a novel putative anxiolytic. Naunyn-Schmiedeberg's Arch Pharmacol 328:467–470Google Scholar
  9. Gammans RE, Mayol RF, Eison MS (1983) Concentration of buspirone and 1-pyrimidinyl-piperazine, a metabolite, in rat brain. Fed Prod 42:377Google Scholar
  10. Gardner CR (1985) Pharmacological studies of the role of serotonin in animal models of anxiety. In: Green AR (ed) Neuropharmacology of serotonin. Oxford University Press, Oxford, pp 281–325Google Scholar
  11. Goa KL, Ward A (1986) Buspirone. A preliminary review of its pharmacological properties and therapeutic efficacy as an anxiolytic. Drugs 32:114–129Google Scholar
  12. Gower AJ (1986) In vivo α2-adrenoceptor antagonist activity of buspirone and its metabolite 1-(2-pyrimidyl)piperazine (1-PP) in the rat. Br J Pharmacol 89:726PGoogle Scholar
  13. Handley SL, Mithani S (1984) Effects of alpha-adrenoceptor agonists and antagonists in a maze exploration model of “fear” motivated behaviour. Naunyn-Schmiedeberg's Arch Pharmacol 327:1–5Google Scholar
  14. Holmberg G, Gershon S (1961) Autonomic and psychic effects of yohimbine hydrochloride. Psychopharmacology 2:93–106Google Scholar
  15. McMillen BA, Mattiace LA (1983) Comparative neuropharmacology of buspirone and MJ-13805, a potential anti-anxiety drug. J Neural Transm 57:255–265Google Scholar
  16. Mir Ak, Hibert M, Tricklebank MD, Middlemiss DN, Kidd EJ, Fozard JR (1988) MDL 72832: a potent and stereoselective ligand at central and peripheral 5-HT1A receptors. Eur J Pharmacol 149:107–120Google Scholar
  17. Moser P, Hibert M, Middlemiss DN, Mir AK, Tricklebank MD, Fozard JR (1988) Effects of MDL 73005EF in animal models predictive of anxiolytic activity. Br J Pharmacol 93:3PGoogle Scholar
  18. Palfreyman MG, Zreika M, Arbogast R, Wagner J (1984) A method for measuring monoamine turnover in animals using an irreversible inhibitor of aromaticl-amino acid decarboxylase, dl-a-mono fluoromethyldopa. J Pharmacol Methods 11:239–251Google Scholar
  19. Pazos A, Palacios JM (1985) Quantitative autoradiographic mapping of serotonin receptors in the rat brain. 1. Serotonin-1 receptors. Brain Res 346:250–230Google Scholar
  20. Pellow S, Chopin P, File SE, Briley M (1985) Validation of openclosed arm entries in an elevated plus-maze as a measure of anxiety in the rat. J Neurosci Methods 14:149–167Google Scholar
  21. Pellow S, Johnston AL, File SE (1987) Selective agonists and antagonists for 5-hydroxytryptamine receptor subtypes, and interactions with yohimbine and FG 7142 using the elevated plus-maze test in the rat. J Pharm Pharmacol 39:917–928Google Scholar
  22. Peroutka S (1985) Selective interaction of novel anxiolytics with 5-hydroxytryptamine1A receptors. Biol Psychiatry 20:971–979Google Scholar
  23. Russell PA (1973) Relationships between exploratory behaviour and fear: a review. Br J Psychol 64:417–433Google Scholar
  24. Söderpalm B, Hjorth S, Engel JA (1988) Effects of serotonergic drugs in Montgomery's conflict test. Psychopharmacology 96:167Google Scholar
  25. Sprouse JS, Aghajanian GK (1986) (-)-Propranolol blocks the inhibition of serotonergic dorsal raphé cell firing by 5-HT1A selective agonists. Eur J Pharmacol 128:295–298Google Scholar
  26. Sprouse JS, Aghajanian GK (1988) Responses of hippocampal pyramidal cells to putative serotonin 5-HT1A and 5-HT1B agonists: a comparative study with dorsal raphé neurones. Neuropharmacology 27:707–715Google Scholar
  27. Traber J, Davies MA, Dompert WU, Glaser T, Schuurman T, Seidel P-R, (1984) Brain serotonin receptors as a target for the putative anxiolytic TVX Q 7821. Brain Res Bull 12:741–744Google Scholar
  28. VanderMaelen CP, Matheson GK, Wilderman RC, Patterson LA (1986) Inhibition of serotonergic dorsal raphé neurons by systemic and iontophoretic administration of buspirone,: a nonbenzodiazepine anxiolytic drug. Eur J Pharmacol 129:123–130Google Scholar
  29. Van der Poel AM (1979) A note on “stretched attention”, a behavioural element indicative of an approach-avoidance conflict in rats. Anim Behav 27:446–450Google Scholar
  30. Vogel JR, Beer B, Clody DE (1971) A simple and reliable conflict procedure for testing anti-anxiety agents. Psychopharmacologia 21:1–7Google Scholar

Copyright information

© Springer-Verlag 1989

Authors and Affiliations

  • P. C. Moser
    • 1
  1. 1.Merrell Dow Research InstituteStrasbourg, CédexFrance

Personalised recommendations